X-linked myotubular myopathy: A prospective international natural history study
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 50 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures. METHODS: We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored. RESULTS: Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti-adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10. CONCLUSIONS: Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population. CLINICALTRIALSGOV IDENTIFIER: NCT02057705.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This contrasts with natural history data wherein XLMTM subjects had a 2.7-point annual decline from baseline in CHOP-INTEND scores and a reduction in MIP over 12 months.40”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [40]
Citations
Cites
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“We also tested for the presence of neutralizing antibodies against adeno-associated virus (AAV) type 8 in serum, as humoral immune response to AAV can prevent AAV vector transduction.(20,21)”
BackgroundFinkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Kishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598
Observational study of spinal muscular atrophy type I and implications for clinical trials
Finkel, R. S., McDermott, M. P., Kaufmann, P., Darras, B. T., Chung, W. K., Sproule, D. M., Kang, P. B., Foley, A. R., Yang, M. L., Martens, W. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000741 · Cited by 528
Self-citationPredicted normal values for maximal respiratory pressures in caucasian adults and children.
Wilson, S. H., Cooke, N. T., Edwards, R. H., & Spiro, S. G. (1984) · Thorax · doi:10.1136/thx.39.7.535 · Cited by 516
Urinary creatinine excretion and lean body mass
Forbes, G., & Bruining, G. (1976) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/29.12.1359 · Cited by 489 · cited 1×
“A 24-hour urine collection every 6 months measured the amount of creatinine excreted as a marker of the skeletal muscle mass.(22) At each visit, the physician performed a complete physical examination, noted concomitant treatments and adverse events, measured vital signs, weight and height, and assessed ophthalmoplegi…”
MethodA motor function measure scale for neuromuscular diseases. Construction and validation study
Bérard, C., Payan, C., Hodgkinson, I., Fermanian, J., & The MFM Collaborative Study Group (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2005.03.004 · Cited by 453
The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21544 · Cited by 397
Glanzman, A. M., Mazzone, E., Main, M., Pelliccioni, M., Wood, J., Swoboda, K. J., Scott, C., Pane, M., Messina, S., Bertini, E., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.11.014 · Cited by 391
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“7-point annual decline from baseline in CHOP-INTEND scores and a reduction in MIP over 12 months.(40) In 2018, following an acknowledgment of the progress made in this trial, the FDA granted AT132 the regenerative medicine advanced therapy (RMAT) designation, equivalent to FDA’s Fast Track and Breakthrough Therapy.”
MethodShieh, P. B., Kuntz, N. L., Dowling, J. J., Müller‐Felber, W., Bönnemann, C. G., Seferian, A., Servais, L., Smith, B. K., Muntoni, F., Blaschek, A., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00313-7 · Cited by 162
“Additional details of these analyses and a summary of study assessments up to week 48 are provided in appendix 1 (pp 6–8, 19–20).”
BackgroundMethodInfluentialSelf-citationCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 162
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study
Annoussamy, M., Seferian, A., Daron, A., Péréon, Y., Cancés, C., Vuillerot, C., Waele, L. D., Laugel, V., Schara, U., Gidaro, T., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51281 · Cited by 136
Self-citationMolecular and cellular basis of genetically inherited skeletal muscle disorders
Dowling, J. J., Weihl, C. C., & Spencer, M. J. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00389-z · Cited by 116
Self-citation
Metadata
- Authors
- Annoussamy, M., Lilien, C., Gidaro, T., Gargaun, E., Chê, V., Schara, U., Gangfuß, A., D'Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., Mayer, M., Cuisset, J.-M., Vuillerot, C., Fontaine, S., Bellance, R., Biancalana, V., Buj-Bello, A., Hogrel, J.-Y., Landy, H., & Servais, L.
- Affiliations
- Boston Children's Hospital (US)
- From I-Motion (M.A., C.L., T.G., E.G., V.C., L.S.), Institute of Myology, Paris, France; Paediatric Neurology and Neuromuscular Center (U.S., A.G.), University of Essen, Germany; Unit of Neuromuscular and Neurodegenerative Disorders (A. D'Amico), Department of Neurosciences, Bambino Gesu Children's Research Hospital IRCCS, Rome, Italy; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.), Hospital for Sick Children, Toronto, Canada; Boston Children's Hospital (B.T.D.), MA;...
- ORCID
- Venue
- Neurology
- Published
- 2019-04-16
- Volume
- 92
- Issue
- 16
- Pages
- e1852-e1867
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC6550499
- OpenAlex
- W2923356198
- Cited by
- 94
- References
- 51
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 15 · 2023: 18 · 2022: 13 · 2021: 17 · 2020: 14 · 2019: 3
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- HAL (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- X-linked myotubular myopathy, natural history (disease), disease progression, outcome measures, muscle strength, respiratory function, forced vital capacity, AAV8, phenotypic heterogeneity, clinical trial readiness
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Follow-Up Studies, Humans, Infant, Longitudinal Studies, Male, Middle Aged, Phenotype, Prospective Studies, Disease Progression, Myopathies, Structural, Congenital, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: X-linked myotubular myopathy: A prospective international natural history study. https://app.cochat.ai/papers/10.1212/wnl.0000000000007319
- The paper
- Annoussamy, M., Lilien, C., Gidaro, T., Gargaun, E., Chê, V., Schara, U., Gangfuß, A., D'Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., Mayer, M., Cuisset, J.-M., Vuillerot, C., Fontaine, S., Bellance, R., . . . Servais, L. (2019). X-linked myotubular myopathy: A prospective international natural history study. Neurology. https://doi.org/10.1212/wnl.0000000000007319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.